Fascinatingly, as part of a multicentre single-arm clinical trial investigating MM resistance (NCT040065789), Cohen et al recently reported that either PPIA/CYPA knockout or inhibition using CsA sensitised resistant MM tumour cells to proteosome inhibition, further underscoring the potential clinical impact of CYPA inhibition (Cohen et al, 2021). This evidence concerns the gene PPIA and Miyoshi myopathy.